Skip to main content

Table 3 Multivariate logistic regression analysis using sRAGE to distinguish HFNO/MV and predict MV

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality

Covariate

HFNO/MV (n = 32/164)

MV (N = 19/164)

OR (95% CI)

p value

OR (95% CI)

p value

sRAGE*

1.782 (1.163–2.730)

0.008

1.389 (1.060–1.820)

0.017

SOFA Score ≥ 3

106.295 (17.102–660.653)

 < 0.001

66.451 (7.343–601.396)

 < 0.001

Age

1.031 (0.957–1.110)

0.419

  

Comorbidity

1.228 (0.161–9.397)

0.843

  

Male gender

4.687 (0.568–38.704)

0.151

  
  1. *per 1000 pg/mL
  2. HFNO/MV high-flow nasal oxygen therapy or mechanical ventilation, sRAGE soluble receptor of advanced glycation end product, SOFA sequential organ failure assessment score